JERUSALEM, May 05, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Cellebrite Announces Fourth Quarter 2022 Results
ARR of $249 million, up 33% year–over–year
Fourth–quarter revenue of $74.0 million, [...] Read more »
Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization
Risk of symptomatic COVID–19 was reduced by 71% compared to placebo in pre–exposure prophylaxis and 75% compared to placebo in post–exposure prophylaxis
Risk of [...] Read more »
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID–19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second [...] Read more »
Bombardier reports its third quarter 2021 results, demonstrates solid execution and strong cash flow performance
- Business aircraft revenues of $1.4 billion, up 17% year–over–year, mainly driven by an improved delivery mix and continued strong aftermarket recovery as overall fleet flight hours surpass 2019 [...] Read more »
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results
New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID–19 to be Presented at IDWeek 2021
Patient Population in Global EVADE Phase 2/3 Clinical [...] Read more »
CORRECTION – Zoom Reports Financial Results for the Second Quarter of Fiscal Year 2022
- Second quarter total revenue of $1,021.5 million, up 54% year over year
- Number of customers [...] Read more »
Zoom Reports Financial Results for the Second Quarter of Fiscal Year 2022
- Second quarter total revenue of $1,021.5 million, up 54% year over year
- Number of customers [...] Read more »
Zoom Video Communications to Release Financial Results for the Second Quarter of Fiscal Year 2022
SAN JOSE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM), a leading provider of frictionless enterprise communications, today announced it will release its financial results for [...] Read more »
Zoom Reports Financial Results for the First Quarter of Fiscal Year 2022
- First quarter total revenue of $956.2 million, up 191% year over year
- Number of customers contributing more than $100,000 in TTM revenue up 160% year over [...] Read more »
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
"' Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3–Month Primary Endpoint; Final Data Including BMD Expected Q2:21 "'
Read more »
Nyxoah Reports Full Year 2020 Results
Nyxoah Reports Full Year 2020 Results
Conference call and webcast today at 3pm CET / 9am ET
Mont–Saint–Guibert, Belgium [...] Read more »